Results

Total Results: 1,541 records

Showing results for "months".

201. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - depending on expert comments received on interventions issued for comment during the preceding 6 months … A 2015 followup survey reported that these results were sustained 6 months after the intervention, … Additionally, after 3 months, significantly fewer SA+F group patients reported any binge drinking days … (baseline: 79.3%; 3 months: 64.8%; change: -14.5 percentage points) than either the control (baseline … : 79.7%; 3 months: 77.7%; change: -2.0 percentage points) or SA (baseline: 78.1%; 3 months: 75.0%;

202. Insomnia_protocol-140403 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_protocol-140716.pdf
     April 03, 2014 - ) and occur despite adequate opportunity for sleep on at least 3 nights per week for at least three months … 17 percent of U.S. adults reporting “regularly having insomnia or trouble sleeping in the past 12 months … timeframe for sleep difficulties; chronic insomnia was used to describe cases that lasted from weeks to months … Timing KQ1: Outcomes measured at 4 weeks to 3 months after initiation of treatment will be used to … o sustained efficacy/comparative effectiveness: over 3 months • subgroups of adults: older adults

203. Insomnia_protocol-140403 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_research-protocol.pdf
     April 03, 2014 - and occur despite adequate opportunity for sleep on at least 3 nights per week for at least three months … 17 percent of U.S. adults reporting “regularly having insomnia or trouble sleeping in the past 12 months … timeframe for sleep difficulties; chronic insomnia was used to describe cases that lasted from weeks to months … Timing KQ1: Outcomes measured at 4 weeks to 3 months after initiation of treatment will be used to … o sustained efficacy/comparative effectiveness: over 3 months • subgroups of adults: older adults

204. FRN 35 - Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
     April 01, 2013 - ” or for “several months”4 seem to contradict the nature of the condition and the length of treatment … ” or for “several months”47 seem to contradict the nature of the condition and the length of treatment … Comparator Preventive pharmacologic treatment (i.e. tricyclic antidepressant) for 3 months followed … Comparator Preventive pharmacologic treatment of 3-, 6- and/or 9-months duration. … Comparator Preventive pharmacologic treatment (e.g. topiramate) for 3 months followed by placebo.

205. Disposition of Comments_Comparative Effectiveness Review No. 265_Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-disposition-comments.pdf
     August 29, 2023 - the authors’ responses to the comments are posted for public viewing on the website approximately 3 months … convey that decision making should seek to balance the impact of treatment frequency in the remaining months … single vs. mutlifraction for cord compression is in a short prognosis patient population (Median OS 3 months … A cord compression study in patients with median survival of 9-12 months says something very different … from a study with a population surviving a median of 3 months.

206. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis—An Update of the 2006 Report. (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-disposition-120516.pdf
     October 01, 2011 - responses to the comments are posted for public viewing on the EHC Program Web site approximately 3 months … Revised to clarify that “end of followup” results were through 12 months (page 17, line 15). … followed by an open-label phase of another 6 months in which patients of both groups received 800 … membrane thickness was assessed at baseline and 6 months. … (p=0.030,) which persisted at 12 months (p=0.021).

207. Behavioral Programs To Help Manage Type 1 Diabetes (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-behavior-programs_consumer-2016.pdf
     January 01, 2016 - programs, helped people with type 1 diabetes better manage their blood sugar in the short term (up to 6 months … How often and for how many months would I need to meet with the trained provider?

208. Noninvasive Treatments for Low Back Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/back-pain-treatment_research_executive.pdf
     February 01, 2016 - pain at some time in their lives, and over one-quarter of U.S. adults report recent (in the last 3 months … and has resulted in pain on at least half the days in the past 6 months.8 Patients with chronic back … There was no difference at 12 months (3 trials; WMD, −0.76; 95% CI, −3.19 to 1.66; I2 = 0%). … There was no difference at 12 months (3 trials; WMD, −0.76; 95% CI, −3.19 to 1.66; I2 = 0%). … (2 trials; SMD, −0.22; 95% CI, −0.38 to −0.06; I2 = 33%), and 12 months (2 trials; SMD, −0.21; 95%

209. Disposition of Comments for Comparative Effectiveness Review 133 Transitional Care Interventions To Prevent Readmissions for People With Heart Failure (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-transition-care_disposition-comments.pdf
     May 27, 2014 - responses to the comments are posted for public viewing on the EHC Program Web site approximately 3 months … Unlike most other recent reviews, this review focuses on short-term outcomes (less than 6 months). … Our review differs mainly in terms of outcome timing (the focus is on readmission rates < 6 months … Unlike most other recent reviews, this review focuses on short-term outcomes (less than 6 months). … , or 12 months, or 2 years?

210. Diabetes-Foot-Ulcer-Amputation-Incidence Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-foot-ulcer-amputation-incidence_research.pdf
     January 01, 2011 - FINDINGS Incidence of Foot Ulcer Among Medicare beneficiaries continu- ously enrolled for at least 12 months … at least a 12-month period of continuous Parts A and B FFS enrollment centering on any one of the months … It is important to note that beneficiaries were considered continuously enrolled for 12 months, centered

211. App-E-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
     May 29, 2025 - 64% Black: 16% Multiracial: 10% Asian: 3% Pacific Islander: 1% Race not known: 4% Pain duration: ≥6 months

212. CER 225: Evidence Summary Interventions for Substance Use Disorders in Adolescents: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-225-substance-abuse-adolescents-evidence-summary%20225%20Substance%20Use%20Adolescents.pdf
     May 01, 2020 - substance use disorders Pharmacological interventions  In opioid use disorder, longer courses (2–3 months

213. Peripheral Nerve Blocks for Postoperative Pain Management in Cardiothoracic Surgery (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-nerve-block-protocol.pdf
     November 18, 2023 - 72 hours of surgery or during the inpatient stay), subacute (discharge up to and including three months … postoperatively), and chronic (greater than 3 and up through 12 months postoperatively). … life (HRQoL) ● Patient satisfaction ● Hospital length of stay ● Cost to patient Long-term (>3 months … subdivided into 72 hours or less; >72 hours or discharge up to <30 days; 30 days up to ≤3 months … Post-operative period 3-12 months  Other timing Setting   Perioperative (inpatient or outpatient

214. Living Systematic Review on Plant-Based Treatment for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/plant-based-treatments-revised-protocol.pdf
     March 29, 2023 - and Objectives for the Systematic Review Chronic pain, defined as pain lasting longer than 3 to 6 months … health care utilization) All KQs: Other outcomes Time of followup All KQs: short term (1 to <6 months … ), intermediate term (6 to <12 months), long term (≥1 year) All KQs: studies with <1-month of treatment … , 6 to 12 months, and ≥12 months).11-13,33,34 Meta-analyses will be conducted to summarize data and … The disposition of comments for systematic reviews and technical briefs will be published 3 months

215. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/14_substanceabuse_potential_high_impact_june_2012.pdf
     January 01, 2012 - depending on expert comments received on interventions issued for comment during the preceding 6 months … program, he or she will be able to receive personalized education text messages over the course of 4 months … The optimal duration of treatment varies, but is typically in the range of 6 months to a year. … up for the program, he or she receives personalized education text messages over the course of 4 months … the system consists of a polymer rod that releases a sustained level of buprenorphine for up to 6 months

216. S44 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s44.pdf
     October 01, 2007 - We initially pro- posed to PharmaCare a delay of 6 or 12 months, and this was left open. … In BC, 3 months is a typical lag time between a policy change and the date it affects those patients … Six months of de- layed savings in 10% of nebulized medication users would equal 2.5 weeks of delayed … After many months of delays, a further delay in savings equal to 2.5 weeks was tolerable to PharmaCare … Whether a drug’s effects are manifested within days or months, influ- ences the perceived appropriateness

217. Outcomes in COPD patients treated with theophylline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/decide16final-mortality-risk-in-copd-pts-using-theophylline.pdf
     December 01, 2009 - The treatment identification period was the six months from October 1, Effective Health Care Research … For each person in the analysis, medication exposure during the six months preceding each day during … We selected six months as our time frame for exposure measurement because we did not want associations … Additionally, six months ensures sufficient time for chronic exposure and includes two dispensings of … The rates of use were approximately 70% or higher over the first 18 months and then decreased in each

218. Outcomes in COPD patients treated with theophylline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/copd-management_research.pdf
     December 01, 2009 - The treatment identification period was the six months from October 1, Effective Health Care Research … For each person in the analysis, medication exposure during the six months preceding each day during … We selected six months as our time frame for exposure measurement because we did not want associations … Additionally, six months ensures sufficient time for chronic exposure and includes two dispensings of … The rates of use were approximately 70% or higher over the first 18 months and then decreased in each

219. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ear-infection_research-protocol.pdf
     August 07, 2012 - at least one episode of OME by age 10, with the majority of cases occurring between the ages of 6 months … and 4 years.2, 3 Many episodes of OME resolve spontaneously within 3 months, but 30 to 40 percent of … with no differences seen at 12 and 18 months. … T: Short-term studies looking at outcomes from 0–3 months postintervention. … Longer term studies looking at outcomes past 3 months and into adolescence or adulthood.

220. Liver-Cancer-Therapy Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_executive.pdf
     May 01, 2013 - The mean TTP was longer in the DEB group (10.6 ± 2.4 months) than the TAE group (9.1 ± 2.3 months; p … after TACE vs. 15.6 months after DEB; p = 0.64). … TACE vs. 13.1 months after DEB). … The median time to disease progression was 9.5 months (range: 1.0 to 47.3 months) in patients treated … with TACE and 10.4 months (range: 1.0 to 42.7 months) in patients treated with RFA (p = 0.95).